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Adenovirus (ADV) infections after hematopoietic cell transplantation (HCT) range in severity from self-
limited to fatal. We have previously reported high mortality rates in CD34þ selected T celledepleted (TCD)
HCT recipients using symptomatic testing and culture methods for ADV detection. We report rates and
outcomes of ADV viremia in 215 adult recipients of TCD HCT using the CliniMACS CD34þ selection system.
This was a prospective observational study of adults transplanted from March 21, 2012 through November 30,
2014 at Memorial Sloan-Kettering Cancer Center. TCD was performed using CliniMACS CD34þ cell selection.
Patients were monitored for ADV by whole blood PCR assay from þ14 to þ100 days post-transplant. ADV
viremia was deﬁned as 1 PCR above the lower limit of quantitation. ADV disease was deﬁned per European
Group for Blood and Marrow Transplantation guidelines. Treatment for ADV was at the clinician’s discretion.
Competing risk regression analyses were used to identify predictors for ADV viremia and overall survival. The
median age was 55 years (range, 22 to 72); 215 patients underwent TCD. All patients received myeloablative
conditioning. Eighteen patients (8% of cohort) had ADV viremia at a median onset of 57 days (interquartile
range [IQR], 23 to 79) and with a median viral load at ﬁrst detection of 2.6 log10 copies/mL (IQR, 2.5 to 4.0).
The median maximal viral load was 4.5 log10 copies/mL (IQR, 3.5 to 5.9). No signiﬁcant risk factor was
identiﬁed for ADV viremia by univariate analysis. Six patients (3% of total cohort, 33% of viremic patients)
developed ADV disease (3 colitis, 2 nephritis/cystitis, 1 pneumonitis). ADV viremia preceded onset of ADV
disease a median of 11 days from the ﬁrst positive quantitative PCR (range, þ3 to þ37) except in 1 patient
with nephritis. Overall, 12 of 18 viremic patients (67%) received antiviral treatment (5 cidofovir only, 7
brincidofovir  cidofovir). All patients with ADV disease were treated, and 6 patients were preemptively
treated for ADV. Among the 18 viremic patients, 8 (44%) died during the study period, and, of those, 4 (22%)
died of ADV. Early ADV viremia was infrequent (8%) among adult HCT recipients of CD34þ selected allografts.
Among viremic patients, rate of ADV disease was 33% and ADV attributable mortality was 22%. Further
studies are needed to assess the impact of preemptive treatment with brincidofovir on improving outcomes
of ADV infections in this patient population.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION METHODS
Adenovirus (ADV) infections after hematopoietic cell
transplantation (HCT) range in severity from self-limited to
fatal [1-11]. We have previously reported high mortality
rates in T celledepleted (TCD) HCT recipients using symp-
tomatic testing for ADV detection [1]. In contrast, low inci-
dence (5% to 12%) and severity is reported among
nonablative HCT, using alemtuzumab for TCD monitored
prospectively by quantitative PCR (qPCR) in the plasma
[6,10]. Since March 2012 we implemented routine ADV qPCR
monitoring in recipients of TCD allografts using the US Food
and Drug Administrationeapproved CliniMACS CD34þ se-
lection system.We report rates and outcomes of ADV viremia
in this patient population.edgments on page 178.
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y for Blood andMarrow Transplantation.Study Patients
The study was reviewed by the Memorial Sloan-Kettering Cancer Center
(MSKCC) Institutional Review Board. The cohort comprised adult patients
transplanted between March 21, 2012 and November 30, 2014 at MSKCC
with CD34þ selected allograft using the CliniMACS system (Miltenyi Biotec,
Gladbach, Germany) [12]. Data were extracted from institutional databases
and medical, microbiology, and pharmacy records.Standards of Care
All patients received myeloablative conditioning [13]. TCD was the sole
modality for graft-versus-host disease (GVHD) prophylaxis. Supportive
care and anti-infective prophylaxis were administered as previously
described [14].Laboratory Methods
Patients were routinely monitored for ADV by plasma qPCR, performed
by Viracor-IBT Laboratories (Lee’s Summit, MO), weekly from day þ14 and
day þ100. Afterward, testing was at clinician discretion for symptomatic
patients. Urine, stool, and respiratory specimens were tested for ADV in
symptomatic patients at clinician discretion. qPCR in stool and urine was
performed by Viracor IBT. Respiratory specimens were tested by the
FilmArray Respiratory Panel (BioFire Diagnostics, Inc., Salt Lake City, UT)
and/or performed by viral culture at the MSKCC microbiology laboratory.
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ADV viremia was deﬁned as 1 PCR above the lower limit of quantita-
tion. ADV disease was deﬁned per European Group for Blood and Marrow
Transplantation guidelines [15]. Death was attributed to ADV if ADV caused
or signiﬁcantly contributed to death.Statistics
Patients were censored at the date of relapse, second HCT, death, or end
of study date (February 28, 2015), whichever occurred ﬁrst. Cumulative
incidence and overall survival were calculated by the Kaplan-Meier method.
The log-rank test was used for comparisons. Stepwise forward Cox pro-
portional hazard regression models were used to identify risk factors for
ADV viremia. The mortality rate was calculated by dividing the total number
of deaths from all causes by the sum of days in patients at risk. The stan-
dardized mortality ratio was deﬁned as the ratio of observed number of
actual deaths to the expected deaths in the study population under the
assumption that the mortality rates for the study population are the same as
those for the reference population [16]. Statistical analyses were performed
using SAS 9.2 (SAS Inc., Cary, NC). A P value .05 was considered statistically
signiﬁcant.RESULTS
ADV Viremia
Table 1 shows the baseline characteristics of the cohort.
Overall, 20 patients (9.3%) developed acute GVHD grade II
and 1 patient acute GVHD grade III.
Eighteen patients (8.4%) developed ADV viremia. The
100-day cumulative incidence of ADV viremia was 8.5%.
The median day of ADV viremia onset was 56.5 days post-
HCT (interquartile range [IQR], 23 to 79). The median ADV
viral load at detection and median maximum viral load were
2.6 log10 copies/mL (IQR, 2.5 to 4.0) and 4.5 log10 copies/mL
(IQR, 3.5 to 5.9), respectively.
The ADV viral load was a major factor inﬂuencing the
decision to start treatment. In the early part of the study, ADV
viral load of 10,000 copies/mL was used as threshold for
treatment based on our previous publication [1]. In the latter
part of the study, because of our increasing clinical experi-
ence and availability of brincidofovir (BCV) at our institution,
there was a trend for earlier treatment. Other factors taken
into consideration were timing of ADV infection post-HCT,
presence of symptoms, and comorbidities. All patients had
more than 1 positive ADV PCR, and most patients had rising
ADV viral load before starting treatment.
Based on antiviral treatment, patients were categorized
into 2 groups: group I (cases A through L) with treatment and
group II (cases M through R) without treatment (Figure 1).
Among group I (n¼ 12), 5 patients received cidofovir only and
7 patients received BCV  cidofovir. The median viral load at
initiation of treatment was 4.6 log10 copies/mL (IQR, 3.8 to 5.7).
Treatment was initiated preemptively in 6 patients (cases G
through L) and for ADV disease in 6 patients (cases A through
F). Among 6 patients preemptively treated for ADV, 4 cleared
the viremia (median total duration of treatment, 7 days [range,
6 to 19]) and 2 had persistent viremia at the time of death. Five
of 6 with ADV disease died, and all had viremia at the time of
death (Figure 1). The median ADV viral load at ﬁrst detection
was 2.5 log10 copies/mL (IQR, 2.2 to 3.0) for patients with ADV
disease (cases A through F), whereas the median ADV viral
load at ﬁrst detection was 4.1 log10 copies/mL (IQR, 3.6 to 4.4)
for patients with preemptive antiviral treatment (cases G
through L).
Patients in group II (n ¼ 6) had low-grade viremia
(maximum viral load median, 3.1 log10 copies/mL; IQR, 2.5 to
3.7), which was transient or intermittent in duration (range,
7 to 45 days) and cleared without treatment. The ADV
viremia onset post-transplant was earlier for group I thangroup II (median 43 days [IQR, 18 to 74] versus 80 days [IQR,
54 to 96], respectively).Risk Factors for ADV Viremia
Host and transplant characteristics listed in Table 1 were
examined in univariate models to identify predictors for ADV
viremia (Table 2). No statistically signiﬁcant predictor was
identiﬁed. Because of a potential association between ADV
infection and GVHD, we examined the relationship between
onset of ADV viremia and GVHD. Among patients with ADV
viremia, 3 patients (16.7%) developed grade II GVHD
(including 2 patients with lower gastrointestinal [GI] GVHD
and 1 with upper GI GVHD). Two patients developed ADV
viremia before onset of GVHD. One patient developedmild GI
GVHD after ADV infection. Symptoms resolved after oral
budesonide treatment for 1 week.CD4þ and CD8þ Lymphocyte Counts at Day þ100 Post-
HCT
Among our cohort, 166 patients had CD4þ and CD8þ
lymphocyte counts measured at day þ100 post-HCT
(including 10 patients with ADV viremia and 156 patients
without ADV viremia). Themedian CD4þ countwas 29 cells/mL
(IQR, 4.3 to 60) in patients with ADV viremia and 65 cells/mL
(IQR, 11 to 208.3) in patients without ADV viremia (P ¼ .255).
The median CD8þ counts was 109 cells/mL (IQR, 30.3 to 161.5)
in patients with ADV viremia and 76 cells/mL (IQR, 3 to 490) in
patients without ADV viremia (P ¼ .9482).Viral Coinfections
Patients with ADV viremia frequently had additional viral
infections by double-stranded DNA viruses. Twelve patients
(67%) had cytomegalovirus, 4 (22%) had Epstein-Barr virus,
and 3 (17%) had human herpesvirus 6 viremia. Eight patients
(44%) had 2 viruses in addition to ADV.ADV Disease
Among 18 viremic patients, 6 (33%) developed disease. The
cumulative incidence of ADV disease was 3.2%. ADV disease
was diagnosed a median of 48 days (IQR, 28 to 56) post-HCT.
The onset of ADV viremia in patients with ADV disease
was a median of 29 days (IQR, 17 to 49) post-transplant. ADV
viremia preceded diagnosis of ADV disease by a median of
11 days (range,þ3 toþ37) in all but 1 patient with nephritis/
hemorrhagic cystitis. In that patient, the detection of ADV in
urine preceded ADV viremia. ADV disease involved the GI
tract in 3 patients, the genitourinary tract in 2 patients, and
the respiratory tract in 1 patient. All patients had ADV in the
stool. In addition, 2 patients had ADV in urine, 1 patient had
ADV in a respiratory specimen, and 2 had ADV in urine and
respiratory specimens.
Medianmaximumviral load was 6.5 log10 copies/mL (IQR,
4.8 to 6.7). Five patients received antivirals after diagnosis of
ADV disease. Patient B developed ADV nephritis/hemor-
rhagic cystitis at day þ26 post-HCT with negative ADV
viremia and received antivirals at day þ54 post-HCT when
she developed ADV viremia (Figure 1). Median viral load at
the time of treatment initiation was 4.5 log10 copies/mL
(range, 2.8 to 6.5). Five patients were treated with BCV; 4
discontinued BCV before disease resolution because of diar-
rhea and ileus or GI bleeding. The median viral load at the
time of death was 4.9 log10 copies/mL (range, 3.2 to 7.5).
Table 1
Baseline Demographics and Transplant Characteristics (N ¼ 215)
Characteristic Value
Median age, yr (range) 55.1 (21.7-72.1)
Sex
Female/male 81 (37.7)/134 (62.3)
Underlying disease
Acute leukemia 93 (43.3)
Multiple myeloma 58 (27.0)
MDS 44 (20.5)
MPD* 12 (5.5)
Lymphoma/chronic lymphocytic leukemia 6 (2.8)
Nonhematologic malignancy 2 (.9)
Conditioning regimen
Busulfan/melphalan/ﬂudarabine 163 (75.8)
TBI/thiotepa/cyclophosphamide 46 (21.4)
Thiotepa/melphalan/clofarabine 6 (2.8)
Recipient CMV serostatus
Negative 89 (41.4)
Positive 126 (58.6)
Donor type, N (%)
Matched related 64 (29.8)
Matched unrelated 107 (49.8)
Mismatched (related or unrelated) 44 (20.4)
Acute GVHD
Grade 0 176 (81.9)
Grade I 18 (8.4)
Grade II 20 (9.3)
Grade III 1 (.5)
Grade IV 0 (.0)
MDS indicatesmyelodysplastic syndrome;MPD,myeloproliferative disease;
TBI, total body irradiation; CMV, cytomegalovirus.
Values are total number of cases with percents in parentheses, unless
otherwise noted.
* MPD: chronic myelomonocytic leukemia in 1 patient, essential throm-
bocytopenia in 2 patients, myeloﬁbrosis in 7 patients, and polycythemia
vera in 2 patients.
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The median follow-up of the cohort was 372 days (range,
29 to 1017). Patients with ADV viremia had higher mortality
compared with patients without ADV viremia (1.21 versus
.62 per 1000 person-days, respectively). Eight of 18 patients
(44%) with ADV viremia died during the study. None of the 8
patients with ADV viremia who died had GVHD at any time
post-HCT. ADV disease was the primary cause of death in
4 patients.
The remaining 4 patients died from other infections
(toxoplasmosis, cytomegalovirus pneumonitis, bacterial
pneumonia, 1 patient each) and acute ﬁbrinous pericarditis
(1 patient). All patients had ongoing ADV viremia at the time
of death.
DISCUSSION
We report rates and outcomes of ADV viremia in a large
cohort of adult recipients of CD34þ selected HCT. The inci-
dence of ADV viremia (8.5%) was similar to reported inci-
dence after nonablative conditioning with alemtuzumab
[6,10]. However, ADV viremia had major clinical implica-
tions and adversely affected overall survival. Among viremic
patients, two thirds required antiviral treatment, one third
developed ADV disease, and one fourth died of ADV. Because
our patients did not receive exogenous GVHD prophylaxis,
reduction of immunosuppression was not possible. The
median CD4þ lymphocyte count at day þ100 post-HCT was
low and similar between patients with and without ADV
viremia (median 29 cells/mL and 65 cells/mL respectively; not
signiﬁcant).
In this cohort of CD34þ selected HCT, we could not
identify any risk factor for ADV viremia by univariate anal-
ysis. Overall rates of GVHD were low, and GVHD of the GI
tract was grade II in almost all cases. Three patients (17%)
with ADV viremia had GI GVHD (grade II), and ADV infection
preceded the onset of mild GVHD in 1 patient only. Thus, we
could not identify any correlation between ADV and GVHD.
Patients with ADV disease in general had early onset of
viremia, at a median of 29 days post-HCT (IQR, 17 to 49). The
interval from detection of viremia to initiation of antiviral
treatment varied because of a lack of standardized guidelines
for managing asymptomatic ADV viremia. Given the short
interval from detection of ADV viremia to ADV disease, we
advocate aggressive treatment of ADV viremia in recipients
of CD34þ selected HCT, especially the ﬁrst 2 months after
transplant. The impact of earlier intervention needs to be
evaluated in clinical studies. Although stool testing was not
routinely done, all patients with ADV disease had ADV in the
stool. Monitoring ADV in stool instead of blood has been of
value in predicting viremia in other settings [3]. The utility of
this approach merits further study in CD34þ selected HCT.
Because of the limited sample size and heterogeneous
antiviral treatment, we cannot conclude on the efﬁcacy of
treatment modalities. Although the decision to start antiviral
therapy was primarily based on ADV viral load, additional
factors were taken into consideration, including timing of
ADV infection post-HCT, presence of symptoms attributable
to ADV, and overall clinical status and concerns for antiviral
treatment-related toxicities. The ﬁrst detected ADV viral load
was higher in patients with preemptive antiviral treatment
compared with patients treated for ADV disease (median 4.1
log10 copies/mL and 2.5 log10 copies/mL, respectively) and
consistent with earlier preemptive treatment for patients
with higher viral copy numbers. Because of increasing clin-
ical experience and availability of BCV (under clinical trial),therewas a trend for earlier treatment in the latter part of the
study [17].
BCV has been shown to be promising for treatment of
ADV [18,19]. BCV was discontinued in 4 patients with
established ADV disease due to GI events (profound diar-
rhea, ileus, bleeding) related to ADV, Clostridium difﬁcile
colitis (1 patient), and/or BCV-induced GI toxicity. Earlier
initiation of BCV, before gut involvement by ADV, may have
improved tolerability. Although ongoing clinical trials of
BCV will provide valuable data on the efﬁcacy of BCV for
preemption of ADV, dedicated trials in adults may be
required because tolerability of BCV may be different in
adult and pediatric patients.
We have previously shown ADV viremia to be a negative
predictor of survival [1]. In the present study, after imple-
mentation of prospective monitoring for ADV, we show that
patients with ADV viremia had higher mortality compared
with patients without viremia. It is of note that imple-
mentation of prospective monitoring was not coupled with
strict guidelines for initiation of treatment. Because of
shorter follow-up in the current study, it is hard to compare
mortality rates before and after implementation of routine
monitoring. Additional differences in the patient population,
including underlying diseases, method of CD34þ selection,
age, and conditioning regimen, may confound comparisons
of mortality rates between 2 noncontemporaneous studies.
Our study has limitations inherent to its observational
nature and sample size. First, heterogeneous clinical man-
agement makes the interpretation of treatment efﬁcacy
challenging. Second, true incidence of ADV disease may be
underestimated, because not all symptomatic patients had
Figure 1. (A) Duration and outcomes of patients with ADV viremia. Each horizontal line represents a patient. X axis indicates days after stem cell infusion; horizontal
line, duration of ADV viremia; , ADV disease diagnosis; D, start of treatment; X, death. All patients had ADV in stool. In addition, 2 patients had ADV in urine, 1 patient
had ADV in a respiratory specimen, and 2 had ADV in urine and respiratory specimens. (B) Patients A through F had ADV disease. VL indicates viral load;
Max, maximum; Tx, treatment; D, day from transplant; CDV, intravenous cidofovir; RESP, respiratory specimens (bronchoalveolar lavage, nasopharyngeal swab).
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resistance genotype) or host genetic or immune predisposi-
tionwere not examined. Acknowledging these limitations, to
our knowledge this is the ﬁrst study to examine the out-
comes of ADV viremia in adult recipients of CD34þ selected
allografts monitored prospectively by ADV qPCR. Given
encouraging outcomes of CD34þ selected HCT and US Food
and Drug Administration approval of the CliniMACS system
for CD34þ selection, the use of CD34þ allografts is likely to
increase in the future [12].
In summary, despite the low incidence among adult
CD34þ selected HCT (8%), ADV viremia was an important
cause of early mortality, adversely affecting early overall
survival. Sive et al. [6], using alemtuzumab for TCD, sug-
gested that ADV viral load and infection responded to
reduction in immunosuppression, whereas we observedrapidly rising ADV viral load and short interval between
onset of ADV viremia and disease in the setting of low CD4þ
post-HCT without exogenous immunosuppression. Routine
monitoring by ADV qPCR in blood was useful in identifying
ADV viremia at low viral loads. Based on our clinical expe-
rience, we recommend treatment for conﬁrmed ADV viral
load >103 copies/mL, if occurring the ﬁrst 2 months after
CD34þ selected HCT. After 2 months post-HCT, we advocate
treatment for rising viral load in consecutive specimens ob-
tained 3 to 4 days apart or viral load >103 copies/mL in the
presence of coinfections or immunosuppressants. Similar
guidelines have been proposed by Lindemans et al. [5] for
recipients of cord blood or TCD allografts. Because of the lack
of exogenous immunosuppression, recipients of CD34þ
selected HCT may beneﬁt from a combined approach of
antivirals and cellular therapy to reconstitute immunity
Table 2
Risk Factors of ADV Viremia during the First 100 Days after CD34þ Selected
HCT
Variable HR (95% CI) P
Age per year 1.0 (1.0-1.1) .47
Sex
Female 1.0
Male 1.2 (.5-3.2) .72
Underlying disease*
Myeloid 1.0
Lymphoid 1.6 (.6-4.0) .37
Donor type
Matched related 1.0
Matched unrelated .4 (.1-1.0) .06
Mismatched .5 (.1-1.7) .24
CMV serostatus
Recipient negative 1.0
Recipient positive 2.6 (.9-7.9) .09
Acute GVHD grade
0-I 1.0
II-IV 1.9 (.6-6.7) .3
HR indicates hazard ratio; CI, conﬁdence interval.
* Myeloid diseases include acute leukemia, myelodysplastic syndrome,
myeloproliferative disease, and nonhematologic malignancies. Lymphoid
diseases include lymphoma, chronic lymphocytic leukemia, and multiple
myeloma.
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selected allografts are needed to improve outcomes of ADV
infection in this population.
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